Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Alpha‐synuclein is a presynaptic protein strongly implicated in Parkinson's disease (PD). Because dopamine neurons are invariably compromised during pathogenesis in PD, we have been exploring the functions of alpha‐synuclein with particular relevance to dopaminergic neuronal cells. We previously discovered reduced tyrosine hydroxylase (TH) activity and minimal dopamine synthesis in stably‐transfected MN9D cells overexpressing either wild‐type or A53T mutant (alanine to threonine at amino acid 53) alpha‐synuclein. TH, the rate‐limiting enzyme in dopamine synthesis, converts tyrosine to l‐dihydroxyphenylalanine (L‐DOPA), which is then converted to dopamine by the enzyme, aromatic amino acid decarboxylase (AADC). We confirmed an interaction between alpha‐synuclein and AADC in striatum. We then sought to determine whether wild‐type or A53T mutant alpha‐synuclein might have affected AADC activity in dopaminergic cells. Using HPLC with electrochemical detection, we measured dopamine and related catechols after L‐DOPA treatments to bypass the TH step. We discovered that while alpha‐synuclein did not reduce AADC protein levels, it significantly reduced AADC activity and phosphorylation in our cells. These novel findings further support a role for alpha‐synuclein in dopamine homeostasis and may explain, at least in part, the selective vulnerability of dopamine neurons that occurs in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“…in familial autosomal dominant PD (A53T, A30P, E46K) (Polymeropoulos et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and by the identification of multiple copies of wild-type a-Syn in rare families with the disease (Singleton et al. 2003; Chartier-Harlin et al. 2004; Ibanez et al. 2004).”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · cited 1×
“…in familial autosomal dominant PD (A53T, A30P, E46K) (Polymeropoulos et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and by the identification of multiple copies of wild-type a-Syn in rare families with the disease (Singleton et al. 2003; Chartier-Harlin et al. 2004; Ibanez et al. 2004).”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824 · cited 1×
“Moreover, in animal models, including transgenic mice (Masliah et al. 2000; Giasson et al. 2002; Lee et al. 2002) and Drosophila (Feany and Bender 2000), pathology results from a-Syn overexpression that includes a-Syn inclusions and some neuronal loss, although animal models vary phenotypically…”
BackgroundPathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693 · cited 1×
“Parkinson’s disease (PD), the second most common neurodegenerative disorder after Alzheimer’s disease, is characterized by motor symptoms that occur after nigro-striatal degeneration and loss of dopaminergic neurons (Braak and Braak 2000).”
BackgroundA Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598 · cited 9×
“We previously identified a role for a-Syn as an inhibitor of dopamine synthesis by binding to and reducing the activity of TH in both cells and in vitro assays (Perez et al. 2002).”
BackgroundMethodSelf-citationBehavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285
Peng, X. M., Tehranian, R., Dietrich, P., Stefanis, L., & Perez, R. G. (2005) · Journal of Cell Science · doi:10.1242/jcs.02481 · Cited by 249 · cited 19×
“All steps were carried out at 4 C as described by Peng et al. (2005), but with minor modifications.”
BackgroundMethodInfluentialSelf-citationα‐Synuclein produces a long‐lasting increase in neurotransmitter release
Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R. D., & Arancio, O. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600451 · Cited by 198
Could a loss of α‐synuclein function put dopaminergic neurons at risk?
Perez, R. G., & Hastings, T. G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02423.x · Cited by 133 · cited 1×
“Together these findings support a key role for a-Syn in the regulation of dopamine synthesis (reviewed in Perez and Hastings 2004).”
BackgroundSelf-citation
Cited by
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J. W., & Uversky, V. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 657
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Calpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration
Vosler, P. S., Brennan, C. S., & Chen, J. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8036-x · Cited by 382
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Bridi, J. C., & Hirth, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00080 · Cited by 378
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., & Björklund, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.013 · Cited by 286
Metadata
- Authors
- Tehranian, R., Montoya, S. E., Van Laar, A. D., Hastings, T. G., & Perez, R. G.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-08-21
- Volume
- 99
- Issue
- 4
- Pages
- 1188-1196
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1967905541
- Cited by
- 114
- References
- 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.